Skip to content
Catalyst
Urine pH

1 finding · 1 compound · 1 null · by evidence strength. No dose is advised.

Fig. 2 Urine pH1 compound outer ring on requestSelected Urine pH · centre
×1.60
Labels
Measured outcomeInspector

Urine pH

Findings drawn, by strength

1finding · 1 compound

  • Moderate1
Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

Compound no difference foundFindingsStrongest
1
Moderate

Not pooled · no summary effect · point at a mark · Tab, then the arrow keys

Measured, no difference found1 finding

  1. InosineMoved: no difference foundEvidence: ModeratePaper: PMID 243661032014
    Who
    Adults with early Parkinson disease not yet requiring symptomatic treatment, serum urate below about 6 mg/dL, without gout, urolithiasis, or cardiovascular or renal disease, at US Parkinson Study Group sites; both inosine arms against placebo; urine pH self-monitored at least daily for the first 12 weeks, with potassium citrate alkalinisation in any arm for persistently acidic urine
    Dose studied
    inosine 500 mg capsules, started at 1 capsule twice daily and titrated up to 2 capsules three times daily (maximum 3 g/day) to serum urate 6.1-7.0 or 7.1-8.0 mg/dL; mean doses 1.18 and 1.51 g/day; up to 24 months

    Need for alkalinization was rare because urine pH was unaffected by inosine (eTables 2 and 3).”

    Quoted verbatim from Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.RCTPermalink

How it is measured

pH of urine (urinary pH) by pH meter or reagent strip, in a spot sample or a timed (usually 24-hour) collection. The collection and the method are recorded with each finding.

Measured, with no finding

3 measurements

Show what was measuredHide what was measured
  • urine pH

    no effect

    Need for alkalinization was rare because urine pH was unaffected by inosine (eTables 2 and 3).

    PMID 24366103 · one of two readings recorded this

  • urine pH

    no effect

    H3Cit did not significantly alter citraturia, calciuria, pH, or ammonium compared with placebo

    PMID 30036516 · one of two readings recorded this

  • urine pH

    increases, p = 0.01

    Compared with placebo and H3Cit, K3Cit led to an increase in urine potassium, citrate and pH (, Table 2), and a decline in urine ammonium (Table 2) (p<0.01 for all)

    PMID 30036516 · one of two readings recorded this

Papers about it

As an endpoint2

Show the papersHide the papers
  • Impact of Potassium Citrate vs Citric Acid on Urinary Stone Risk in Calcium Phosphate Stone Formers.

    The Journal of urology2018PMID 30036516Via: named in the paper, as read

  • Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

    JAMA neurology2014PMID 24366103Via: named in the paper, as read

Newest

  • Impact of Potassium Citrate vs Citric Acid on Urinary Stone Risk in Calcium Phosphate Stone Formers.

    The Journal of urology2018PMID 30036516As an endpoint

  • Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

    JAMA neurology2014PMID 24366103As an endpoint